Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Müllerian hormone and somatic ovarian function: a new perspective.

Journal of assisted reproduction and genetics·2026
Same author

Corrigendum to "Failure of podocalyxin suppression and HOXA10/HOXA11 activation characterizes endometrial dysfunction in hyperandrogenic PCOS" [Mol. Cell. Endocrinol 616 (2026) 112763].

Molecular and cellular endocrinology·2026
Same author

Tissue Accessibility as a Missing Determinant of Immunomodulatory and Platelet-Rich Plasma Therapy Success in Infertility: A Conceptual Framework.

American journal of reproductive immunology (New York, N.Y. : 1989)·2026
Same author

Failure of podocalyxin suppression and HOXA10/HOXA11 activation characterizes endometrial dysfunction in hyperandrogenic PCOS.

Molecular and cellular endocrinology·2026
Same author

Thin Endometrium Restricts Peri-ovulatory Physiological Transition Between Anti-adhesive and Adhesive Receptivity Modulators.

Obstetrical & gynecological survey·2025
Same author

Thin endometrium restricts peri-ovulatory physiological transition between anti-adhesive and adhesive receptivity modulators.

Reproductive biomedicine online·2025

Related Experiment Video

Updated: Jul 3, 2026

Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
08:02

Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue

Published on: January 6, 2012

Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.

Onder Celik1, Seyma Hascalik, Koray Elter

  • 1Department of Obstetrics and Gynecology, Inonu University School of Medicine, 44069, Malatya, Turkey. oncelik@inonu.edu.tr

Human Reproduction (Oxford, England)
|August 5, 2008
PubMed
Summary

Pyrrolidine dithiocarbamate (PDTC) and bortezomib effectively reduced experimental endometriosis in rats. These nuclear factor-kappaB and proteasome inhibitors decreased implant size and cell proliferation, suggesting a new therapeutic approach for endometriosis.

Related Experiment Videos

Last Updated: Jul 3, 2026

Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue
08:02

Mouse Model of Surgically-induced Endometriosis by Auto-transplantation of Uterine Tissue

Published on: January 6, 2012

Area of Science:

  • Reproductive biology
  • Pharmacology
  • Oncology

Background:

  • Endometriosis is a condition where uterine tissue grows outside the uterus.
  • Current treatments for endometriosis have limitations.
  • Novel therapeutic strategies are needed to manage endometriosis effectively.

Purpose of the Study:

  • To investigate the efficacy of pyrrolidine dithiocarbamate (PDTC) and bortezomib in treating experimental endometriosis in a rat model.
  • To assess the impact of these agents on endometriotic implant development and cellular markers.

Main Methods:

  • Surgically induced endometriosis in 30 rats.
  • Administered PDTC and bortezomib to treatment groups, with a control group.
  • Measured implant volume and assessed expression of Ki67, PCNA, CD34, CD31, and Masson's trichrome post-treatment.

Main Results:

  • PDTC and bortezomib significantly reduced endometriotic implant volumes compared to controls (P < 0.002 and P < 0.001, respectively).
  • Treatment decreased the incidence of larger vesicles (Grades 3 and 4) and increased Grade 1 (no vesicle).
  • Reduced expression of proliferation markers (Ki67, PCNA) and angiogenesis markers (CD34, CD31) was observed in treated groups.

Conclusions:

  • PDTC and bortezomib demonstrate significant therapeutic potential for endometriosis.
  • These agents may offer a novel treatment strategy by inhibiting implant growth and vascularization.
  • Further research is warranted to explore their clinical application in endometriosis management.